Santalis Pharmaceuticals specializes in the development of dermatology drugs based on Sandalwood Album Oil (SAO).
US-based Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of Quintis Ltd. of Perth, Australia (ASX:QIN). Santalis was formed to develop a range of prescription and OTC products based on the botanical drug substance produced by Quintis’ Santalum album trees. Santalis has the world-wide exclusive rights to Quintis’ Sandalwood Album Oil (SAO) for healthcare uses. Quintis is the world’s largest producer of this essential oil and is the only supplier of pharmaceutical-grade SAO from sustainably-grown trees. Santalis is developing SAO under the FDA’s botanical drug development guidelines, with a current focus on dermatology. Indications of particular interest include acne, rosacea, atopic dermatitis/eczema, psoriasis and viral skin diseases such as Molluscum contagiosum and warts caused by human papilloma virus (HPV).